TNFSF13B/CD257 (Belimumab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-TNFSF13B/CD257 (Belimumab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | TNFSF13B/CD257 (Belimumab biosimilar) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 lambda |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Belimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1? monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain. |
| Immunogen | n/a |
| Other Names | Belimumab, TNFSF13B/CD257, 356547-88-1 |
| Gene, Accession # | CAS: 356547-88-1 |
| Catalog # | abx831148 |
| Price | please inquire |
| Order / More Info | TNFSF13B/CD257 (Belimumab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies